PortfoliosLab logoPortfoliosLab logo
NVS vs. SNY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVS vs. SNY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novartis AG (NVS) and Sanofi (SNY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVS achieves a 10.91% return, which is significantly higher than SNY's -3.34% return. Over the past 10 years, NVS has outperformed SNY with an annualized return of 10.15%, while SNY has yielded a comparatively lower 5.00% annualized return.


NVS

1D
3.30%
1M
1.99%
YTD
10.91%
6M
15.47%
1Y
30.77%
3Y*
18.32%
5Y*
14.79%
10Y*
10.15%

SNY

1D
4.74%
1M
2.35%
YTD
-3.34%
6M
-4.21%
1Y
-5.37%
3Y*
0.11%
5Y*
0.98%
10Y*
5.00%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NVS vs. SNY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NVS
Novartis AG
10.91%46.95%0.02%16.14%8.06%-3.65%3.34%13.92%5.95%19.42%
SNY
Sanofi
-3.34%4.93%1.09%6.55%0.57%7.00%0.39%20.47%6.06%9.96%

Correlation

The correlation between NVS and SNY is 0.53, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.53

Correlation (3Y)
Calculated over the trailing 3-year period

0.50

Correlation (5Y)
Calculated over the trailing 5-year period

0.53

Correlation (10Y)
Calculated over the trailing 10-year period

0.54

Correlation (All Time)
Calculated using the full available price history since Jul 2, 2002

0.55

The correlation between NVS and SNY has been stable across timeframes, ranging from 0.50 to 0.55 - a consistent structural relationship.

Fundamentals

Market Cap

NVS:

$284.33B

SNY:

$106.88B

EPS

NVS:

$6.99

SNY:

$3.09

PE Ratio

NVS:

21.23

SNY:

14.37

PS Ratio

NVS:

5.13

SNY:

2.29

PB Ratio

NVS:

7.38

SNY:

1.47

Total Revenue (TTM)

NVS:

$56.05B

SNY:

$47.35B

Gross Profit (TTM)

NVS:

$42.19B

SNY:

$34.18B

EBITDA (TTM)

NVS:

$22.40B

SNY:

$12.63B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVS vs. SNY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVS
NVS Risk / Return Rank: 7878
Overall Rank
NVS Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
NVS Sortino Ratio Rank: 7777
Sortino Ratio Rank
NVS Omega Ratio Rank: 7575
Omega Ratio Rank
NVS Calmar Ratio Rank: 7979
Calmar Ratio Rank
NVS Martin Ratio Rank: 7979
Martin Ratio Rank

SNY
SNY Risk / Return Rank: 3030
Overall Rank
SNY Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
SNY Sortino Ratio Rank: 2828
Sortino Ratio Rank
SNY Omega Ratio Rank: 2828
Omega Ratio Rank
SNY Calmar Ratio Rank: 3131
Calmar Ratio Rank
SNY Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVS vs. SNY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NVSSNYDifference
Sharpe ratioReturn per unit of total volatility

+1.72

Sortino ratioReturn per unit of downside risk

+2.24

Omega ratioGain probability vs. loss probability

1.26

0.98

+0.28

Calmar ratioReturn relative to maximum drawdown

2.44

-0.32

+2.77

Martin ratioReturn relative to average drawdown

6.09

-0.64

+6.73

NVS vs. SNY - Sharpe Ratio Comparison

The current NVS Sharpe Ratio is 1.51, which is higher than the SNY Sharpe Ratio of -0.21. The chart below compares the historical Sharpe Ratios of NVS and SNY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NVSSNYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.51

-0.21

+1.72

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.79

0.04

+0.75

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.52

0.21

+0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.42

0.21

+0.21

Drawdowns

NVS vs. SNY - Drawdown Comparison

The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum SNY drawdown of -46.46%. Use the drawdown chart below to compare losses from any high point for NVS and SNY.


Loading charts...

Drawdown Indicators


NVSSNYDifference

Max Drawdown

Largest peak-to-trough decline

-42.10%

-46.46%

+4.36%

Max Drawdown (1Y)

Largest decline over 1 year

-12.65%

-16.70%

+4.05%

Max Drawdown (3Y)

Largest decline over 3 years

-19.95%

-23.37%

+3.42%

Max Drawdown (5Y)

Largest decline over 5 years

-20.42%

-33.52%

+13.10%

Max Drawdown (10Y)

Largest decline over 10 years

-26.03%

-33.52%

+7.49%

Current Drawdown

Current decline from peak

-9.31%

-17.67%

+8.36%

Average Drawdown

Average peak-to-trough decline

-10.93%

-12.19%

+1.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.06%

8.47%

-3.41%

Volatility

NVS vs. SNY - Volatility Comparison

The current volatility for Novartis AG (NVS) is 6.49%, while Sanofi (SNY) has a volatility of 7.22%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVSSNYDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.49%

7.22%

-0.73%

Volatility (6M)

Calculated over the trailing 6-month period

14.39%

15.69%

-1.30%

Volatility (1Y)

Calculated over the trailing 1-year period

20.52%

25.40%

-4.88%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

18.83%

24.77%

-5.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

19.61%

23.46%

-3.85%

Dividends

NVS vs. SNY - Dividend Comparison

NVS's dividend yield for the trailing twelve months is around 3.22%, less than SNY's 5.46% yield.


PositionTTM20252024202320222021202020192018201720162015
NVS
Novartis AG
3.22%2.90%3.84%3.44%3.70%3.86%3.22%3.03%3.47%3.24%3.73%3.10%
SNY
Sanofi
5.46%4.56%4.22%3.83%4.32%3.80%3.61%3.47%4.29%3.82%4.11%3.77%

Financials

NVS vs. SNY - Financials Comparison

This section allows you to compare key financial metrics between Novartis AG and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


8.00B10.00B12.00B14.00B20222023202420252026
13.52B
11.24B
(NVS) Total Revenue
(SNY) Total Revenue
Values in USD except per share items

NVS vs. SNY - Profitability Comparison

The chart below illustrates the profitability comparison between Novartis AG and Sanofi over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

66.0%68.0%70.0%72.0%74.0%76.0%78.0%20222023202420252026
74.4%
72.1%
Portfolio components
NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.


Frequently Asked Questions


NVS and SNY have a correlation of 0.53, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SNY has higher volatility (7.22%) compared to NVS (6.49%). In terms of maximum drawdown, NVS dropped -42.10% vs SNY's -46.46%.

NVS currently has the higher Sharpe Ratio (1.51 vs -0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVS and SNY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer